Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer

K. S. Anderson, J. Wong, Gypsyamber D'Souza, A. B. Riemer, J. Lorch, R. Haddad, S. I. Pai, J. Longtine, M. McClean, J. Labaer, K. T. Kelsey, M. Posner

Research output: Contribution to journalArticle

Abstract

Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.

Original languageEnglish (US)
Pages (from-to)1896-1905
Number of pages10
JournalBritish Journal of Cancer
Volume104
Issue number12
DOIs
StatePublished - Jun 7 2011

Fingerprint

Proteome
Head and Neck Neoplasms
Biomarkers
Carcinoma
Antibodies
Serum
Proteins
Human papillomavirus 16
Capsid
Oncogene Proteins
Fluorescence
Viruses

Keywords

  • autoantibodies
  • biomarker
  • head and neck cancer
  • HPV
  • Luminex

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anderson, K. S., Wong, J., D'Souza, G., Riemer, A. B., Lorch, J., Haddad, R., ... Posner, M. (2011). Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. British Journal of Cancer, 104(12), 1896-1905. https://doi.org/10.1038/bjc.2011.171

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. / Anderson, K. S.; Wong, J.; D'Souza, Gypsyamber; Riemer, A. B.; Lorch, J.; Haddad, R.; Pai, S. I.; Longtine, J.; McClean, M.; Labaer, J.; Kelsey, K. T.; Posner, M.

In: British Journal of Cancer, Vol. 104, No. 12, 07.06.2011, p. 1896-1905.

Research output: Contribution to journalArticle

Anderson, KS, Wong, J, D'Souza, G, Riemer, AB, Lorch, J, Haddad, R, Pai, SI, Longtine, J, McClean, M, Labaer, J, Kelsey, KT & Posner, M 2011, 'Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer', British Journal of Cancer, vol. 104, no. 12, pp. 1896-1905. https://doi.org/10.1038/bjc.2011.171
Anderson, K. S. ; Wong, J. ; D'Souza, Gypsyamber ; Riemer, A. B. ; Lorch, J. ; Haddad, R. ; Pai, S. I. ; Longtine, J. ; McClean, M. ; Labaer, J. ; Kelsey, K. T. ; Posner, M. / Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. In: British Journal of Cancer. 2011 ; Vol. 104, No. 12. pp. 1896-1905.
@article{5989450bc5fc41309ce818529042aa3b,
title = "Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer",
abstract = "Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.",
keywords = "autoantibodies, biomarker, head and neck cancer, HPV, Luminex",
author = "Anderson, {K. S.} and J. Wong and Gypsyamber D'Souza and Riemer, {A. B.} and J. Lorch and R. Haddad and Pai, {S. I.} and J. Longtine and M. McClean and J. Labaer and Kelsey, {K. T.} and M. Posner",
year = "2011",
month = "6",
day = "7",
doi = "10.1038/bjc.2011.171",
language = "English (US)",
volume = "104",
pages = "1896--1905",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer

AU - Anderson, K. S.

AU - Wong, J.

AU - D'Souza, Gypsyamber

AU - Riemer, A. B.

AU - Lorch, J.

AU - Haddad, R.

AU - Pai, S. I.

AU - Longtine, J.

AU - McClean, M.

AU - Labaer, J.

AU - Kelsey, K. T.

AU - Posner, M.

PY - 2011/6/7

Y1 - 2011/6/7

N2 - Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.

AB - Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.

KW - autoantibodies

KW - biomarker

KW - head and neck cancer

KW - HPV

KW - Luminex

UR - http://www.scopus.com/inward/record.url?scp=79958087380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958087380&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.171

DO - 10.1038/bjc.2011.171

M3 - Article

C2 - 21654689

AN - SCOPUS:79958087380

VL - 104

SP - 1896

EP - 1905

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -